|
|
1681 Chestnut Street, Suite 400
Vancouver, BC V6J 4M6 Canada
phone:604.331.0400
fax:604.331.0877 |
| Symbol |
GMXX |
| Exchange |
.OB |
| Founded |
0 |
| Employees |
|
|
|
| www.genemax.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Disease treatments through technologies based on cellular and molecular immunology advances. |
|
| Management |
| Wilfred A. Jefferies, Chairman of the Board and Chief Scientific Officer; Aris Morfopoulos, President, Chief Executive Officer, Principal Executive Officer, Director; Patrick A. McGowan, Chief Financial Officer, Treasurer, Secretary, Director |
|
|
|
|
| Keywords |
| cancer vaccine, immune system, infectious diseases, autoimmune disorders, transplant tissue rejection, InfectiousDisease |
|
|
|
|
| Description |
|
GeneMax Corp. is a biotechnology company investigating disease treatments through technologies based on cellular and molecular immunology advances. The companyës strategic vision is to develop and market therapeutics based on this technology aimed at cancer, infectious diseases, autoimmune disorders and transplant tissue rejection. |
|
| Products / Services |
TAP-1 cancer vaccine
|
|
| Technology / Differentiation |
| The TAP-1 cancer vaccine restores the ability of the bodys immune system to recognize the cancer cells as foreign. The vaccine boosts the natural process for destroying the cancerous cells. The process involves delivering the TAP-1 gene via a viral vector (adenovirus or vaccinia virus) to the cancer cells to recreate the missing TAP pathway. With TAP pathway restored by the vaccine, the immune system recognizes the cancer cells as foreign and an immune response is initiated to eliminate these cells. |
|
| Market / Customers |
GeneMaxs TAP-1 therapeutic cancer vaccine is a technology targeted towards a group of cancers deficient in the TAP protein, which includes lung cancer, liver cancer, kidney cancer, head and neck cancer, breast cancer, melanoma, prostate cancer, colorectal cancer, and cervical cancer. Cancers are able to grow undetected in the body as they lack the proper signals on their cell surface to alert the immune system of their presence. Due to this property, most cancer cells proliferate in the body.
|
|
| Status |
| The therapeutic cancer vaccine has been proven in successful animal trials: mice infected with a murine lung cancer have experienced up to 70% survival rates following treatment with the vaccine. Recent studies have indicated that the vaccine is also effective in the treatment of melanoma in mice studies. |
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
